Akèy › Limfòm Burkitt › Distrik Columbia › Washington
Etid klinik pou Limfòm Burkitt nan Washington, DC
9 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
- Children's National Medical Center, Washington D.C.
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi lwen
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- Children's National Medical Center, Washington D.C.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
- Children's National Medical Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Etid Limfòm Burkitt nan lòt vil
- Houston, TX21 etid
- Philadelphia, PA16 etid
- Milwaukee, WI16 etid
- Chicago, IL15 etid
- Cincinnati, OH13 etid
- New York City, NY13 etid
- Atlanta, GA12 etid
- Aurora, CO11 etid
- Seattle, WA11 etid
- Durham, NC10 etid
- Kansas City, MO10 etid
- Boston, MA10 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Kansè ovè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.